Rituximab

Results: 190



#Item
71Immunosuppressants / Connective tissue diseases / Arthritis / Autoimmune diseases / Rheumatology / Tocilizumab / Rheumatoid arthritis / Rituximab / Genentech / Health / Medicine / Anatomy

Background Information Roche in Rheumatology: Changing the Treatment of Rheumatoid Arthritis Rheumatoid Arthritis: the treatment gap The prevalence of rheumatoid arthritis (RA) varies between 0.3% and 1% worldwide and i

Add to Reading List

Source URL: www.roche.com

Language: English - Date: 2011-05-26 01:00:00
72Microsoft Word - PRTX_SCIR.doc

Microsoft Word - PRTX_SCIR.doc

Add to Reading List

Source URL: scr.zacks.com

Language: English - Date: 2013-09-16 11:37:44
73Background Information Roche in Rheumatology: Changing the Treatment of Rheumatoid Arthritis Rheumatoid Arthritis: the treatment gap The prevalence of rheumatoid arthritis (RA) varies between 0.3% and 1% worldwide and i

Background Information Roche in Rheumatology: Changing the Treatment of Rheumatoid Arthritis Rheumatoid Arthritis: the treatment gap The prevalence of rheumatoid arthritis (RA) varies between 0.3% and 1% worldwide and i

Add to Reading List

Source URL: www.roche.com

Language: English - Date: 2011-05-26 01:00:00
74National Cancer Drugs Fund List Ver3.1 Ver3.1 National CDF List

National Cancer Drugs Fund List Ver3.1 Ver3.1 National CDF List

Add to Reading List

Source URL: www.england.nhs.uk

Language: English - Date: 2015-01-22 16:13:36
75Available online http://arthritis-research.com/content/8/6/R167 Research article Vol 8 No 6 Open Access

Available online http://arthritis-research.com/content/8/6/R167 Research article Vol 8 No 6 Open Access

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Language: English
76Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence *Not reported

Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence *Not reported

Add to Reading List

Source URL: patients.aan.com

Language: English - Date: 2009-11-10 12:34:40
77 pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical s

pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical s

Add to Reading List

Source URL: www.pcodr.ca

Language: English - Date: 2015-01-09 16:28:10
78 considerably higher than the manufacturer’s estimates. pERC agreed that the EGP’s re-analysis estimates were more reliable than those provided by the submitter and concluded that ofatumumab + chlorambucil is not co

considerably higher than the manufacturer’s estimates. pERC agreed that the EGP’s re-analysis estimates were more reliable than those provided by the submitter and concluded that ofatumumab + chlorambucil is not co

Add to Reading List

Source URL: www.pcodr.ca

Language: English - Date: 2014-12-04 16:10:34
79JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of[removed]Therapeutic Area Product Name

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of[removed]Therapeutic Area Product Name

Add to Reading List

Source URL: files.shareholder.com

Language: English
80Velcade-II-72 Summary of opinion

Velcade-II-72 Summary of opinion

Add to Reading List

Source URL: www.ema.europa.eu

Language: English - Date: 2014-12-19 07:36:07